CRLF2 and acute lymphoblastic leukemia: These investigations emphasize the concept of combined TKI therapy against multiple crosstalk kinases, including PI3K, BLNK, and RAS-MAPK, to overcome the JAKi resistance in CRLF2-rearranged B-ALL [27,38].